1
|
Sharman WM, Allen CM and van Lier JE:
Photodynamic therapeutics: Basic principles and clinical
applications. Drug Discov Today. 4:507–517. 1999. View Article : Google Scholar : PubMed/NCBI
|
2
|
Agostinis P, Berg K, Cengel KA, Foster TH,
Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel
D, et al: Photodynamic therapy of cancer: An update. CA Cancer J
Clin. 61:250–281. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Moore JV, West CM and Whitehurst C: The
biology of photodynamic therapy. Phys Med Biol. 42:913–935. 1997.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Wachowska M, Muchowicz A, Firczuk M,
Gabrysiak M, Winiarska M, Wańczyk M, Bojarczuk K and Golab J:
Aminolevulinic acid (ALA) as a prodrug in photodynamic therapy of
cancer. Molecules. 16:4140–4164. 2011. View Article : Google Scholar
|
5
|
Ishizuka M, Abe F, Sano Y, Takahashi K,
Inoue K, Nakajima M, Kohda T, Komatsu N, Ogura S and Tanaka T:
Novel development of 5-aminolevurinic acid (ALA) in cancer
diagnoses and therapy. Int Immunopharmacol. 11:358–365. 2011.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Nokes B, Apel M, Jones C, Brown G and Lang
JE: Aminolevulinic acid (ALA): Photodynamic detection and potential
therapeutic applications. J Surg Res. 181:262–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Amo T, Kawanishi N, Uchida M, Fujita H,
Oyanagi E, Utsumi T, Ogino T, Inoue K, Shuin T, Utsumi K and Sasaki
J: Mechanism of cell death by 5-aminolevulinic acid-based
photodynamic action and its enhancement by ferrochelatase
inhibitors in human histiocytic lymphoma cell line U937. Cell
Biochem Funct. 27:503–515. 2009. View
Article : Google Scholar : PubMed/NCBI
|
8
|
Ji HT, Chien LT, Lin YH, Chien HF and Chen
CT: 5-ALA mediated photodynamic therapy induces autophagic cell
death via AMP-activated protein kinase. Mol Cancer Ther. 9:912010.
View Article : Google Scholar
|
9
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: A new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Del Barco S, Vazquez-Martin A, Cufí S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation-implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Dowling RJ, Goodwin PJ and Stambolic V:
Understanding the benefit of metformin use in cancer treatment. BMC
Med. 9:332011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW,
Su WP, Chen HH and Su WC: Metformin enhances cisplatin cytotoxicity
by suppressing signal transducer and activator of transcription-3
activity independently of the liver kinase B1-AMP-activated protein
kinase pathway. Am J Respir Cell Mol Biol. 49:241–250. 2013.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Lin YC, Wu MH, Wei TT, Lin YC, Huang WC,
Huang LY, Lin YT and Chen CC: Metformin sensitizes anticancer
effect of dasatinib in head and neck squamous cell carcinoma cells
through AMPK-dependent ER stress. Oncotarget. 5:298–308.
2014.PubMed/NCBI
|
19
|
Song CW, Lee H, Dings RP, Williams B,
Powers J, Santos TD, Choi BH and Park HJ: Metformin kills and
radiosensitizes cancer cells and preferentially kills cancer stem
cells. Sci Rep. 2:3622012. View Article : Google Scholar : PubMed/NCBI
|